Replies to post #13638 on Kraig Biocraft Laboratories Inc (KBLB)

[King Bolaba]

It may be that a company such as DuPont would have the scientific brain power to make an evaluation of the silkworm spider silk in house without the need to publicly release information for peer review. It may be in the best interest of a potential company considering buying out KBLB to keep things quiet relative to "discovery" for the same reasons Kim wants to hold off on publication. No need in giving competitors a head start. jmo Go KBLB

[manshoon1]

I never thought of it that way JimB.
My guess is that Kim would entertain potential partners at notre dame and let Dr Frazier do the talking scientifically. We do have the right to commercialize it, so I think the odds are in favor of some kind of commercial deal soonish. Whether the deal gets announced when it happens is anyones guess, Kim may want to keep that quiet for a bit as well. I would agree that a buyout as an option likely has no validity until at least gen 2 completion, which would most likely coincide with the scientific journal timeframe.

[xjag]

I agree that the peer reviewed paper[s] will probably be published prior to any business announcement. Professors live and die by the quality of their research and publication history. I'm sure you've all heard "publish or perish" and it applies even to tenured professors in huge private universities such as Notre Dame. The scientists have almost certainly secured rights to take scholarly credit for these discoveries and will exercise that right before cashing in on their financial reward. Don't forget, they're shareholders too.

I seem to remember that Kim mentioned in the shareholder conference call that he was not interested in a buyout, but inferred that he wanted to maintain control of the commercialization of transgenic silk worms. Everything that's happened to this point adds weight to this opinion.